Expertise in
1
conditions

Dr. Robert G. Irwin

Hematology | Oncology
MultiCare Health System
315 Martin Luther King Jr Way, 
Tacoma, WA 
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
MultiCare Health System
315 Martin Luther King Jr Way, 
Tacoma, WA 

Overview

Robert Irwin is a Hematologist and an Oncologist practicing medicine in Tacoma, Washington.

Dr. Irwin is highly rated in 1 condition, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Classical Hodgkin Lymphoma, Ewing Sarcoma, Hepatoblastoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 43 clinical trials. Dr. Irwin is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in WA

Languages Spoken

English
Hindi
Portuguese
Romanian
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

MultiCare Health System
315 Martin Luther King Jr Way, Tacoma, WA 98405

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

43 Clinical Trials

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Refractory alveolar rhabdomyosarcoma in an 11-year-old male.
Refractory alveolar rhabdomyosarcoma in an 11-year-old male.
Journal: Cold Spring Harbor molecular case studies
Published: November 01, 2020
Similar Doctors
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (29.0 miles away)
206-987-2000
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Hawkins is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration. Dr. Hawkins is currently accepting new patients.

Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (29.0 miles away)
206-987-2106
Languages Spoken:
English, Castilian, French, Hindi, Mandarin, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Leary is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Leary is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Gliomatosis Cerebri, Brain Tumor, and Bone Marrow Aspiration. Dr. Leary is currently accepting new patients.

Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (29.0 miles away)
206-987-2106
Languages Spoken:
English, Afrikaans, Korean, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

James Olson is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Olson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Glioma. Dr. Olson is currently accepting new patients.

Frequently Asked Questions about Dr. Robert G. Irwin

How do I make an appointment with Dr. Robert G. Irwin?

You can book an appointment with Dr. Robert G. Irwin by calling their office at 253-403-1425. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert G. Irwin a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert G. Irwin is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert G. Irwin specialize in?

While Dr. Robert G. Irwin is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Classical Hodgkin Lymphoma, and Ewing Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Robert G. Irwin participate in research or clinical trials?

Yes. Dr. Robert G. Irwin has published 1 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Robert G. Irwin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert G. Irwin accept my insurance?

Dr. Robert G. Irwin accepts most major insurance plans, including Blue Cross Blue Shield and Cambia Health Solutions. We recommend calling the office directly at 253-403-1425 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Irwin's expertise for a condition
ConditionClose
      View All 48 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile